PDGFRB and neoplasm: Furthermore, in vivo studies are needed to map the PDGFRβ-centered PTM network in stromal cells and TME, to clarify its contribution to CRC progression, and to evaluate whether inhibiting these pathways—alone or in combination with immunotherapy—can improve tumor control.